Literature DB >> 2956619

Characterization of intra-tumoral porphyrin following injection of hematoporphyrin derivative or its purified component.

T J Dougherty, T S Mang.   

Abstract

Photodynamic therapy (PDT) utilizes either hematoporphyrin derivative (Hpd) or a purified form of Hpd termed DHE, as photosensitizers for treatment of a variety of solid tumors in man. The reasons for long retention of these porphyrins in a wide range of histologically diverse tumors remain obscure. We have found that the RIF fibrosarcoma and SMT-F mammary carcinoma in mice, a intrapancreatic tumor in the hamster and a tumor removed from a patient with a myxoid sarcoma, make take up Hpd or DHE by endocytosis. On the other hand the RIF tumor cells in vitro show a tendency for selective uptake and retention of the more hydrophobic components of the mixture.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2956619     DOI: 10.1111/j.1751-1097.1987.tb04737.x

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  5 in total

1.  Binding of porphyrin to human serum albumin. Structure-activity relationships.

Authors:  S Cohen; R Margalit
Journal:  Biochem J       Date:  1990-09-01       Impact factor: 3.857

2.  Cholangiocarcinoma treatment.

Authors:  Halim Charbel; Firas H Al-Kawas
Journal:  Curr Gastroenterol Rep       Date:  2012-12

3.  Pulsed versus continuous wave excitation mechanisms in photodynamic therapy of differently graded squamous cell carcinomas in tumor-implanted nude mice.

Authors:  P C Rausch; F Rolfs; M R Winkler; A Kottysch; A Schauer; W Steiner
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

4.  Tumour scanning with indium-111 dihaematoporphyrin ether.

Authors:  M R Quastel; A M Richter; J G Levy
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

5.  Effects of photodynamic therapy on xenografts of human mesothelioma and rat mammary carcinoma in nude mice.

Authors:  S L Gibson; T H Foster; R H Feins; R F Raubertas; M A Fallon; R Hilf
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.